---
title: "广东众生药业股份有限公司 (002317.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/002317.SZ.md"
symbol: "002317.SZ"
name: "广东众生药业股份有限公司"
industry: "制药"
---

# 广东众生药业股份有限公司 (002317.SZ)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 沪深市场 |
| Website | [www.zspcl.com](https://www.zspcl.com) |

## Company Profile

公司始创于 1979 年，于 2009 年在深圳证券交易所上市，是一家致力于人类健康事业的中国医药工业百强企业。公司贯彻 “患者利益至上” 的价值观，秉承 “以优质产品关爱生命，以优质服务健康大众” 的企业宗旨，立足于眼科、心脑血管、呼吸、消化等治疗领域，旗下拥有十家子公司、四大生产基地，矢志成为中国一流的医药健康产业集团。公司业务目前主要为药品研发、生产、销售。公司主要产品：来瑞特韦片、昂拉地韦片、复方血栓通系列产品、脑栓通胶囊、复方丹参片、众生丸系列产品、清热祛湿颗粒、羧甲司坦口服溶液 (片)、头孢克肟分散片、头孢拉定胶囊、注射用单磷酸阿糖腺苷、利巴韦林片、异烟肼片、吡嗪酰胺片、盐酸乙胺丁...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: C (0.55)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 91 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.04% |  |
| Net Profit YoY | -248.88% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 4.00 |  |
| Dividend Ratio | 1.06% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 16.11B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.45B |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -4.69% | D |
| Profit Margin | -8.06% | D |
| Gross Margin | 54.27% | B |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.04% | C |
| Net Profit YoY | -248.88% | E |
| Total Assets YoY | -11.21% | E |
| Net Assets YoY | -9.19% | D |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -1240.31% | E |
| OCF YoY | 0.04% | C |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.45 | C |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 20.16% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 广东众生药业股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-4.69%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-8.06%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "54.27%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.04%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-248.88%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-11.21%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-9.19%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-1240.31%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "0.04%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.45",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "20.16%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 兴齐眼药 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恒瑞医药 (SH.600276) | A | B | C | A | B | B |
| 04 | 云南白药 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -81.60 | 205/222 | 72.58 | 70.97 | 68.98 |
| PB | 4.00 | 167/222 | 4.52 | 3.82 | 2.42 |
| PS (TTM) | 6.58 | 147/222 | 7.35 | 6.22 | 4.04 |
| Dividend Yield | 1.06% | 96/222 | 1.71% | 1.12% | 0.95% |

## References

- [Company Overview](https://longbridge.com/en/quote/002317.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/002317.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/002317.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.